MartinLutherKing
19 minutes ago
Dr. Tom Fitzgerald joined Steve Darling from Proactive to announce a major milestone: the dosing of the first two patients in the company’s Phase 1 clinical trial for its lead candidate, TTX-MC138. This clinical trial is a multicenter, open-label, dose-escalation, and dose-expansion study designed t